Efinopegdutide - Hanmi Pharmaceutical
Alternative Names: GLP-1/glucagon-agonist; Glucagon-like-peptides/glucagon; Glucagon/GLP-1-agonist; HM-12525A; JNJ 5111; JNJ-64565111; LAPS GLP/GCG; LAPS-GCG/GLP-1; LAPS-GLP-1/GCG; LAPS-GLP/Glucagon; LAPS-OXM; MK-6024; Oxyntomodulin immunoglobulin conjugateLatest Information Update: 15 Jul 2024
At a glance
- Originator Hanmi Pharmaceutical
- Developer Hanmi Pharmaceutical; Janssen Pharmaceuticals; Merck & Co
- Class Antihyperglycaemics; Gastrointestinal hormones; Glucagon-like peptides; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Jul 2024 Merck Sharp & Dohme plans a phase II trial for Non-alcoholic fatty liver disease (In adults, In the elderly) (SC, Injection), in August 2024 (NCT06482112)
- 18 Jun 2024 Merck Sharp & Dohme plans a phase II trial for Liver cirrhosis in July 2024 (SC) (NCT06465186)
- 22 Nov 2023 Merck Sharp & Dohme initiates a phase I pharmacokinetic trial in Healthy volunteers and participants with Hepatic impairment in USA (SC) (NCT06052566)